PortalPublikationenGeriatric assessment and biomarkers in patients with metasta...

Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial

Standard

Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial. / Honecker, Friedemann; Harbeck, Nadia; Schnabel, Claudia; Wedding, Ulrich; Waldenmaier, Dirk; Saupe, Steffen; Jäger, Elke; Schmidt, Marcus; Kreienberg, Rolf; Müller, Lothar; Otremba, Burkhard; Dorn, Julia; Warm, Mathias; Al-Batran, Salah-Eddin; de Wit, Maike; PELICAN investigators.

in: J GERIATR ONCOL, Jahrgang 9, Nr. 2, 03.2018, S. 163-169.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Honecker, F, Harbeck, N, Schnabel, C, Wedding, U, Waldenmaier, D, Saupe, S, Jäger, E, Schmidt, M, Kreienberg, R, Müller, L, Otremba, B, Dorn, J, Warm, M, Al-Batran, S-E, de Wit, M & PELICAN investigators 2018, 'Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial', J GERIATR ONCOL, Jg. 9, Nr. 2, S. 163-169. https://doi.org/10.1016/j.jgo.2017.09.009

APA

Honecker, F., Harbeck, N., Schnabel, C., Wedding, U., Waldenmaier, D., Saupe, S., Jäger, E., Schmidt, M., Kreienberg, R., Müller, L., Otremba, B., Dorn, J., Warm, M., Al-Batran, S-E., de Wit, M., & PELICAN investigators (2018). Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial. J GERIATR ONCOL, 9(2), 163-169. https://doi.org/10.1016/j.jgo.2017.09.009

Vancouver

Honecker F, Harbeck N, Schnabel C, Wedding U, Waldenmaier D, Saupe S et al. Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial. J GERIATR ONCOL. 2018 Mär;9(2):163-169. https://doi.org/10.1016/j.jgo.2017.09.009

Bibtex

@article{e9195562f48e468082dc8ad70d19f1ae,
title = "Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial",
abstract = "OBJECTIVES: To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA).MATERIALS AND METHODS: Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional index (PINI), and Glasgow prognostic score (GPS) as biomarkers were analyzed for association with clinical outcome within the randomized phase III PEg-LIposomal Doxorubicin vs. CApecitabin iN MBC (PELICAN) trial of first-line pegylated liposomal doxorubicin (PLD) or capecitabine.RESULTS: Of 210 patients, 38% were >65years old. GA (n=152) classified 74% as fit, 10% as compromised, and 16% as frail. Biomarkers showed no age dependency. In multivariate analysis (n=70) KPS, GA, cumulative illness rating scale-geriatrics (CIRS-G), and GPS were significantly associated with time to progression, and KPS, CIRS-G, and instrumental activities of daily living (IADL) from GA, and PINI showed a significant correlation with overall survival.CONCLUSION: GA evaluation was feasible. KPS significantly correlated with efficacy outcomes. Items of a GA and biomarkers of inflammation and nutrition may have prognostic significance in patients with MBC.",
keywords = "Journal Article",
author = "Friedemann Honecker and Nadia Harbeck and Claudia Schnabel and Ulrich Wedding and Dirk Waldenmaier and Steffen Saupe and Elke J{\"a}ger and Marcus Schmidt and Rolf Kreienberg and Lothar M{\"u}ller and Burkhard Otremba and Julia Dorn and Mathias Warm and Salah-Eddin Al-Batran and {de Wit}, Maike and {PELICAN investigators}",
note = "Copyright {\textcopyright} 2017 Elsevier Inc. All rights reserved.",
year = "2018",
month = mar,
doi = "10.1016/j.jgo.2017.09.009",
language = "English",
volume = "9",
pages = "163--169",
journal = "J GERIATR ONCOL",
issn = "1879-4068",
publisher = "Elsevier Limited",
number = "2",

}

RIS

TY - JOUR

T1 - Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial

AU - Honecker, Friedemann

AU - Harbeck, Nadia

AU - Schnabel, Claudia

AU - Wedding, Ulrich

AU - Waldenmaier, Dirk

AU - Saupe, Steffen

AU - Jäger, Elke

AU - Schmidt, Marcus

AU - Kreienberg, Rolf

AU - Müller, Lothar

AU - Otremba, Burkhard

AU - Dorn, Julia

AU - Warm, Mathias

AU - Al-Batran, Salah-Eddin

AU - de Wit, Maike

AU - PELICAN investigators

N1 - Copyright © 2017 Elsevier Inc. All rights reserved.

PY - 2018/3

Y1 - 2018/3

N2 - OBJECTIVES: To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA).MATERIALS AND METHODS: Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional index (PINI), and Glasgow prognostic score (GPS) as biomarkers were analyzed for association with clinical outcome within the randomized phase III PEg-LIposomal Doxorubicin vs. CApecitabin iN MBC (PELICAN) trial of first-line pegylated liposomal doxorubicin (PLD) or capecitabine.RESULTS: Of 210 patients, 38% were >65years old. GA (n=152) classified 74% as fit, 10% as compromised, and 16% as frail. Biomarkers showed no age dependency. In multivariate analysis (n=70) KPS, GA, cumulative illness rating scale-geriatrics (CIRS-G), and GPS were significantly associated with time to progression, and KPS, CIRS-G, and instrumental activities of daily living (IADL) from GA, and PINI showed a significant correlation with overall survival.CONCLUSION: GA evaluation was feasible. KPS significantly correlated with efficacy outcomes. Items of a GA and biomarkers of inflammation and nutrition may have prognostic significance in patients with MBC.

AB - OBJECTIVES: To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA).MATERIALS AND METHODS: Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional index (PINI), and Glasgow prognostic score (GPS) as biomarkers were analyzed for association with clinical outcome within the randomized phase III PEg-LIposomal Doxorubicin vs. CApecitabin iN MBC (PELICAN) trial of first-line pegylated liposomal doxorubicin (PLD) or capecitabine.RESULTS: Of 210 patients, 38% were >65years old. GA (n=152) classified 74% as fit, 10% as compromised, and 16% as frail. Biomarkers showed no age dependency. In multivariate analysis (n=70) KPS, GA, cumulative illness rating scale-geriatrics (CIRS-G), and GPS were significantly associated with time to progression, and KPS, CIRS-G, and instrumental activities of daily living (IADL) from GA, and PINI showed a significant correlation with overall survival.CONCLUSION: GA evaluation was feasible. KPS significantly correlated with efficacy outcomes. Items of a GA and biomarkers of inflammation and nutrition may have prognostic significance in patients with MBC.

KW - Journal Article

U2 - 10.1016/j.jgo.2017.09.009

DO - 10.1016/j.jgo.2017.09.009

M3 - SCORING: Journal article

C2 - 29055624

VL - 9

SP - 163

EP - 169

JO - J GERIATR ONCOL

JF - J GERIATR ONCOL

SN - 1879-4068

IS - 2

ER -